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Abstract  
Background: pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for 
treatment. 
Objective: to estimate the effectiveness of topical therapies in the treatment of PG. 
Methods:  prospective cohort study of UK secondary care patients with a clinical diagnosis of PG suitable for 
topical treatment (recruited July 2009 to June 2012). Participants received topical therapy following normal 
clinical practice (mainly Class I-III topical corticosteroids, tacrolimus 0.03% or 0.1%).  Primary outcome: speed 
of healing at 6 weeks. Secondary outcomes: proportion healed by 6 months; time to healing; global 
assessment; inflammation; pain; quality-of-life; treatment failure and recurrence. 
Results: Sixty-six patients (22 to 85 years) were enrolled. Clobetasol propionate 0.05% was the most commonly 
prescribed therapy. Overall, 28/66 (43.8%) of ulcers healed by 6 months. Median time-to-healing was 145 days 
(95% CI: 96 days, ∞). Initial ulcer size was a significant predictor of time-to-healing (hazard ratio 0.94 (0.88; 
1.00); p = 0.043). Four patients (15%) had a recurrence. 
Limitations: No randomised comparator 
Conclusion: Topical therapy is potentially an effective first-line treatment for PG that avoids possible side-
effects associated with systemic therapy. It remains unclear whether more severe disease will respond 
adequately to topical therapy alone. 
 
Key words: pyoderma gangrenosum, topical therapy, corticosteroid, tacrolimus, side-effects, cohort 
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Abbreviations 
Pyoderma Gangrenosum (PG) 
Randomised controlled trial (RCT) 
EuroQol 5 Dimensions, 3 Levels (EQ-5D-3L) 
Dermatology Life Quality Index (DLQI) 
Tumour Necrosis Factor (TNF) 
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Introduction 
Pyoderma Gangrenosum (PG) is an uncommon, painful ulcerative inflammatory dermatosis that is associated 
with considerable morbidity1, 2 and a reported three-fold increased risk of death3. 
The most commonly prescribed treatments for PG are systemic therapies (e.g. prednisolone, ciclosporin, 
intravenous immunoglobulin or biologic therapies). Nevertheless, topical treatments (e.g. corticosteroids and 
calcineurin inhibitors) have also been recommended for localised disease4, 5 and may be a useful first-line 
therapy for some patients. 
We conducted a multi-centre prospective cohort study to investigate the efficacy of topical therapy as a first-
line treatment for PG.  This cohort study was conducted alongside a randomised controlled trial (RCT) of 
systemic treatments for PG (STOP GAP Trial), in which oral prednisolone was compared to ciclosporin.6 
Our objective was to provide prospectively collected estimates of treatment response for patients receiving 
topical therapy for their PG.  
Methods 
Ethics and regulatory approvals were obtained; participants gave written informed consent. Independent Trial 
Steering Committee and Data Monitoring Committees provided oversight. 
Study design 
Prospective cohort study of patients with a clinical diagnosis of PG, for whom topical therapy was indicated. 
Patients with more severe PG (requiring systemic therapy) were enrolled into the parallel RCT6 but were 
eligible for inclusion in the topical therapy cohort study if systemic therapy was contra-indicated, or if patient 
preference was to receive topical treatment. 
Participants were enrolled for up to 6 months, or until the target PG ulcer had healed. Medications were 
prescribed as per local practice at the recruiting hospital.  
Research questions 
1. What is the typical treatment response in patients for whom topical therapy is indicated? 
2. What proportion of participants require escalation of treatment to systemic medication? 
3. What is the impact of PG on patient-reported quality of life? 
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4. What factors predict treatment response? 
Participants 
Recruitment took place in 28 secondary care hospitals throughout the UK.  Participants were identified from 
dermatology, rheumatology, gastroenterology and general medicine clinics. 
Participants were aged 18 years or older and had a clinical diagnosis of PG (confirmed by the recruiting 
dermatologist, with biopsy to exclude alternative aetiologies if clinically indicated), and at least one 
measureable ulcer. The decision over whether to treat with topical therapy or not was based on the views of 
the dermatologist in discussion with patients.  
Patients were excluded if they had pustular or granulomatous PG variants (as they may respond differently to 
therapy and measurement of a single ulcer was not possible); if they had received oral prednisolone, 
ciclosporin or intravenous immunoglobulin for the treatment of PG in the previous month, or were 
participating in another clinical trial.  
Ongoing treatment with systemic therapies for the management of underlying co-morbidities (e.g. rheumatoid 
arthritis) was permitted.  
Interventions 
Patients received topically applied interventions for the treatment of PG. The dermatologist was free to 
prescribe whichever therapy and dosage regimen they preferred according to local practice. In the UK, normal 
practice would be to apply topical interventions to the inflammatory edge of the ulcer. Systemic therapies for 
the treatment of PG were prohibited, but were continued if taken for other conditions.  
Assessments and outcomes 
Study visits took place at 2 weeks, 6 weeks and 6 months (or at time of healing if sooner).  Other unscheduled 
consultations took place as per normal practice. 
A target lesion was used for outcome assessment. Lesion size was captured by the treating dermatologist 
based on maximal longitudinal length and maximum perpendicular length, converted to area by the formula 
(length x width x 0.785), which approximates an ellipse.  
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Outcomes: i) speed of healing at 6 weeks (primary outcome in-line with RCT primary outcome); ii) proportion 
healed by 6 months; iii) time to healing; iv) global assessment of improvement at 6 weeks and final visit; v) 
inflammation assessment at 6 weeks and final visit7; vi) pain in the first 6 weeks (scored daily 0 to 4); vii) 
quality-of-life (EuroQol 5 Dimensions, 3 Levels – EQ-5D-3L8 & Dermatology Life Quality Index - DLQI9.  
Healing was defined as the point at which dressings were no longer required. This was reported by the 
participants, and a clinic visit was arranged to confirm healing as soon as possible thereafter. In cases where 
the date on which dressings were stopped was unavailable, healing was assumed to have taken place on the 
day that the ulcer was confirmed as healed by the recruiting dermatologist. Pain scores and use of dressings 
were collected using daily diaries.  
Measures taken to control bias 
This was an open study, with no control group. In order to mitigate the risk of bias, consecutive participants 
were enrolled into the study and followed up prospectively. Outcomes were assessed using standard methods 
and clinicians’ and patients’ views were compared where appropriate. Every effort was made to maintain 
follow-up of all participants. 
Sample size 
This was a pragmatic cohort study. No formal sample size calculation was performed, as this was a descriptive 
study without formal between-treatment comparisons. 
Statistical analysis 
The primary analysis included all participants who received at least one topical medication and had available 
data at both the baseline and the 6 week visit. Pre-defined sub-groups were i) participants who received 
clobetasol propionate 0.05%, and ii) participants who received a topical calcineurin inhibitor (tacrolimus or 
pimecrolimus). 
Data are presented descriptively and data relating to participants of the STOP GAP RCT are included alongside 
those of the topical therapy cohort, but no formal comparisons have been made. 
7 
 
 
 
If a participant received more than one topical medication, they were included in all relevant study 
populations. Participants who withdrew due to lack of treatment response, or who started a systemic 
medication during the period of the study were classed as treatment failures for the topical medication. 
Exploratory analyses adjusting for lesion size at baseline, presence of underlying autoimmune disease, age, 
weight, sex and size of recruiting centre were conducted to determine possible factors associated with 
treatment response. Linear regression models were used for continuous outcomes, logistic regression for 
binary outcomes and cox proportional hazards for time to event outcomes. 
Results 
Participants and treatment allocation 
Recruitment took place between July 2009 and June 2012.   
In total, 67 participants were enrolled in the study, but one was subsequently excluded from the analysis 
having received oral prednisolone for PG (Figure 1).  
Forty-nine (74.2%) participants received clobetasol propionate 0.05% (Dermovate™, GlaxoSmithKline); 10 
(15.2%) received tacrolimus 0.03% or 0.1% (Protopic®; Astellas Pharma); and eight received other topical 
interventions including other topical corticosteroids (n=6), fludroxycortide impregnated tape (Haelan® Tape, 
Typharm) (n=1), and lymecycline (Tetralysal® 300, Galderma) (n=1). One participant received both clobetasol 
propionate and tacrolimus and was therefore included in both sub-groups. Five participants in the clobetasol 
propionate group were taking concurrent anti-inflammatory/immune modifying medications for the treatment 
of other conditions including azathioprine (n = 2), tetracyclines (n = 2) and anti-TNF (n = 1). 
The reason for choosing systemic or topical therapy (and therefore eligibility for the cohort study or the RCT), 
were: topical treatment failure - for those opting for systemic therapy (n=47); features of the disease (n=43); 
and patient’s preference (n=6).  
Details of demographic and baseline characteristics are summarised (Table 1: Baseline characteristics of 
participants in STOP GAP RCT and topical therapies cohort study 
Table 2: Treatment response (RCT participants and observational cohort) 
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). The majority of participants were identified through dermatology services (47; 71.2%); others were 
identified from gastroenterology (7; 10.6%), rheumatology (1; 1.5%), general medicine (2.0; 3%) and other 
sources (9; 13.6%).  
Baseline characteristics for participants in the cohort study were broadly similar to those enrolled in the 
parallel RCT, with the exception that the mean lesion size was smaller (4.7cm2 versus 9cm2), the mean number 
of ulcers was lower (1.6 versus 2.4), and fewer participants had had PG previously (18% versus 31%) (Table 1).  
Adherence to medication 
Only 12/66 (18.2%) participants provided data on adherence to their prescribed treatments at the end of the 
study. Nevertheless, the levels of treatment response achieved would suggest that the participants were using 
their medications broadly as prescribed.  Nine participants in the clobetasol propionate group used systemic 
medication for comorbidities during the study (azathioprine n=2; anti-TNF n=1; tetracyclines n=2). 
Treatment response 
Details of the clinical outcomes are summarised (Table 2).  
Mean speed of healing was -0.1 cm2 per day (SD 0.3). This is approximately half that observed in the RCT 
patients receiving systemic therapy, but the method of assessment was different for the two studies (physical 
measurements by clinician versus planimetry from digital images), and so direct comparison is difficult. The 
mean change from baseline in area of the lesion at the final visit was –4.2 (SD 11.5)cm2, with similar changes 
reported in the clobetasol and tacrolimus sub-groups (–4.0 (SD 11.9) and –3.9 (SD 6.0), respectively).   
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Overall, 28 (43.8%) participants healed on topical therapy alone within the 6-month study period. Twenty two 
(33.3%) required systemic therapy, and of these 13 (59.1%) went on to be enrolled into the RCT (Figure 1). For 
those that entered the RCT, 8 (61.5%) healed by 6 months, with 3 of the 13 (23.1%) healing by 6 weeks. 
Ulcers healed in a median duration of 145 days (95% CI: 96 days, ∞) (Table 2, Figure 2). Cox proportional 
hazards model suggested that size of initial lesion was an important predictive factor in determining time to 
healing (HR 0.94 (95% CI: 0.88, 1.00); p = 0.043). Presence of underlying autoimmune disease was not 
predictive (HR 0.90 (95% CI: 0.41, 1.95); p = 0.786).  
Global disease severity, as reported by clinicians and patients, is summarised (Figure 3, Figure 4). Self-reported 
pain gradually reduced during the first 6 weeks of treatment, and quality of life scores improved for both 
disease specific (DLQI) and general health status (EQ-5D-3L) questionnaires (Table 2). No covariates were 
predictive of scores at final visit for any of these outcomes, other than baseline scores for DLQI and EQ-5D VAS 
(DLQI estimate –0.47 (95% CI –0.77, –0.17); p = 0.003. EQ-5D VAS estimate –0.40 (95% CI: –0.65, –0.15); p = 
0.003). 
Recurrence 
Of the 28 participants whose ulcer had healed, 27 had recurrence data available (minimum follow-up from 
time of healing 5.5 months; maximum follow-up 37.2 months). Overall 4/27 (14.8%) participants had a 
recurrence subsequent to their initial episode. 
Discussion  
Main findings  
This prospective cohort study of patients receiving topical therapy for the treatment of PG suggests that many 
patients with limited PG can be managed effectively with topical therapy alone. For almost half of the 
participants, healing was achieved within the 6-month study window and most of these had healed within 2 
months. This is similar to the proportions healed in the STOP GAP RCT, where again roughly half of the ulcers 
had healed by 6 months. Care should be taken when comparing healing rates between the RCT and the cohort 
study as participants in the RCT had more severe disease, as demonstrated by the increased number of ulcers, 
larger ulcer size at baseline, and greater impact on quality of life. Of those who failed to heal on topical 
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therapy, one third subsequently received systemic therapy; suggesting that not all patients can be adequately 
treated with topical therapy alone.  
The most important predictor of time to healing was size of the ulcer at presentation. This is consistent with 
previous findings10. 
Given the increased mortality risk for patients with PG compared to patients with inflammatory bowel disease 
and apparently healthy individuals,3 it is important to evaluate the role of topical therapies for the 
management of PG. Similar concerns about increased mortality and morbidity in bullous pemphigoid patients 
(that could be partly due to systemic therapies such as prednisolone), led to an RCT by Joly et al. who found 
that mortality was reduced in those treated with potent topical steroids compared to those receiving systemic 
steroids.11  
The potential impact of PG on patients’ quality of life is high. Baseline EQ-5D-3L scores of 0.59 (cohort study) 
and 0.48 (RCT) are comparable to patients with mild to severe heart failure; where EQ-5D-3L scores of 0.78 (SD 
0.18) to 0.51 (SD 0.21) respectively have been reported.12 
One of the objectives of this study was to maintain contact with potential trial participants in order to improve 
recruitment into the RCT. In this regard, the cohort study was extremely effective, and resulted in an 
additional 13/121 (11%) patients being enrolled into the RCT. For trials of rare conditions, where the evidence 
base is limited, the added complexities and expense of running a parallel study of this kind can often be 
warranted.13  
Strengths and limitations 
This multi-centre study is much larger than any of the previously published prospective cohort studies of PG 
patients.4, 5, 14 Clinicians prescribed topical medication in line with local practice, but treatment allocations 
were not randomised. As a result, it is not possible to make formal comparison of different topical treatments 
such as corticosteroids versus tacrolimus. Data on sub-groups of patients are presented for interest, but 
should be interpreted cautiously. Tacrolimus may be an effective treatment for PG, but further evaluation in 
comparison to topical corticosteroids is required. Very little is known about the natural history of PG if left 
untreated. In the absence of placebo control arm, it is not possible to say whether or not the lesions would 
have healed without intervention, although clinical experience would suggest that this is unlikely. 
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Generalisability 
This was a pragmatic study that reflected current practice. For an uncommon condition such as PG it was 
necessary to recruit across many hospitals, which aids the generalisabilty of the results. Nevertheless, this 
cohort of patients was recruited alongside an RCT of systemic treatments for PG and this may have impacted 
on the type of patients agreeing to take part. Patients with more severe disease were randomised into the RCT 
and those with milder or more localised disease entered the cohort study. 
Clinical conclusions 
Mild PG may be controlled effectively using topical agents without incurring the side-effects associated with 
systemic treatments. The importance of ulcer size on presentation in determining treatment response, and the 
relatively high recurrence rates are findings that will assist clinicians in optimising the management of PG, and 
in managing patients’ expectations with regards to the potential effectiveness of treatments. 
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Table 1: Baseline characteristics of participants in STOP GAP RCT and topical therapies cohort study 
  RCT  Cohort study  Cohort sub-groups 
  n= 112 n = 66 
clobetasol 
propionate n=49 
tacrolimus 
n= 10 
Demographics 
Age: years Mean (SD) 54.4 (16.3) 57.3 (17.3) 57.5 (17.9) 53.0 (13.0) 
Sex: n (%) Female 73 (65.2) 44 (66.7) 34 (69.4) 6 (60.0) 
Ethnicity: n (%) White 108 (96.4) 64 (97.0) 47 (95.9) 10 (100.0) 
Weight: kg Mean (SD) 90.7 (25.8) 80.4 (20.3) 77.8 (17.2) 86.2 (29.7) 
Medical History 
Underlying    co-
morbidities: n (%) 
 
Crohn’s Disease 8 (7.1) 6 (9.1) 2 (4.1) 2 (20.0) 
Ulcerative colitis 15 (13.4) 8 (12.1) 7 (14.3) 1 (10.0) 
Rheumatoid 
arthritis 
8 (7.1) 2 (3.0) 2 (4.1) 0 (0.0) 
Other 
inflammatory 
arthritis 
6 (5.4) 5 (7.6) 3 (6.1) 2 (20.0) 
Monoclonal 
gammopathy 
0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0) 
Myeloma 0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0) 
Haematological 
malignancy 
0 (0.0) 1 (1.5) 1 (2.0) 0 (0.0) 
Other malignancy 4 (3.6) 6 (9.1) 5 (10.2) 0 (0.0) 
Diabetes 13 (11.6) 7 (10.6) 5 (10.2) 2 (20.0) 
Renal impairment 2 (1.8) 3 (4.5) 2 (4.1) 0 (0.0) 
Epilepsy 1 (0.9) 1 (1.5) 1 (2.0) 0 (0.0) 
Characteristics of PG 
Type of PG: n (%) 
 
Classical 97 (86.6) 55 (83.3) 43 (87.8) 9 (90.0) 
Cribriform 6 (5.4) 1 (1.5) 0 (0.0) 0 (0.0) 
Peristomal 4 (3.6) 6 (9.1) 3 (6.1) 1 (10.0) 
Bullous 1 (0.9) 2 (3.0) 2 (4.1) 0 (0.0) 
Unsure 4 (3.6) 2 (3.0) 1 (2.0) 0 (0.0) 
Previous episode 
of PG: 
Yes n (%) 31 (27.7) 18 (27.3) 12 (24.5) 3 (30.0) 
Area of target 
lesion: cm2 
n 112 65 48 10 
Median (Q1; Q3) 9.0 (3.2, 24.4) 4.7 (2.4; 11.0) 4.4 (1.6; 10.5) 6.8 [2.8, 11.0] 
Location of lesion: 
n (%) 
Upper limb 3 (2.7) 7 (10.6) 6 (12.2) 0 (0.0) 
Lower limb 75 67.0) 39 (59.1) 29 (59.2) 6 (60.0) 
Other 34 (30.4) 20 (30.3) 14 (28.6) 4 (40.0) 
Number of lesions 
 n=110 n = 65 (n = 48) (n=10) 
Mean (SD) 2.4 (2.1) 1.6 (1.2) 1.6 (1.1) 1.8 (1.1) 
 n 112 66 49 10 
Erytherma 
n (%) 
None 6 (5.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Slight 5 (4.5) 9 (13.6) 10 (20.4) 1 (10.0) 
Moderate  36 (32.1) 10 (15.2) 15 (30.6) 8 (80.0) 
Severe 39 (34.8) 32 (48.5) 16 (32.7) 1 (10.0) 
Very Severe 26 (23.2) 15 (22.7) 8 (16.3) 0 (0.0) 
 n= 112 65 49 10 
Border Elevation 
n (%) 
None 5 (4.5) 14 (21.5) 6 (12.2) 0 (0.0) 
Slight 53 (47.3) 23 (35.4) 24 (49.0) 1 (10.0) 
Moderate  36 (32.1) 23 (35.4) 17 (34.7) 8 (80.0) 
Severe 13 (11.6) 4 (6.2) 1 (2.0) 1 (10.0) 
Very Severe 5 (4.5) 1 (1.5) 1 (2.0) 0 (0.0) 
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Exudate 
n (%) 
n= 112 66 49 10 
None 4 (3.6) 8 (12.1) 9 (18.4) 0 (0.0) 
Slight 16 (14.3) 13 (19.7) 12 (24.5) 1 (10.0) 
Moderate  59 (52.7) 27 (40.9) 22 (44.9) 8 (80.0) 
Severe 15 (13.4) 11 (16.7) 4 (8.2) 1 (10.0) 
Very Severe 18 (16.1) 7 (10.6) 2 (4.1) 0 (0.0) 
 
 
Table 2: Treatment response (RCT participants and cohort participants) 
   Sub-groups  
 RCT participants 
n=112 
All cohort participants 
n = 66 
clobetasol propionate 
n=49 
tacrolimus 
n= 10 
Speed of healing n= 108 n = 54 n = 37 n = 10 
Mean (SD) cm2/day -0.2 (0.8) -0.1 (0.3) -0.1 (0.2)  -0.1 (0.1)  
% healed by final visit  
(up to 6 months) 
n=112 n=64 n=47 n= 10 
n (%) 53 (47.3) 28 (43.8) 20 (42.6) 5 (50.0)  
Time to healing (days) n=112 n=64 n=47 n= 10 
Median (95% CI) 169 days (113; ∞) 145 days (96; ∞) 136 days (46; ∞) 161 days (13; ∞) 
Area of lesion: cm2 * n = 108 n=55 n=38 n= 10 
Baseline: median (Q1; Q3) 9.0 (3.2; 24.8) 5.9 (1.8; 13.6) 6.4 (1.6; 14.0) 6.8 (2.8; 11.0)  
Final visit: median (Q1; Q3) 0.0 (0.0; 8.1) 0.0 (0.0; 9.0)  0.0 (0.0; 9.0) 1.2 (0.0; 3.5)  
Mean change from baseline at final visit (SD) -9.1 (51.1) -4.2 (11.5) -4.0 (11.9) -3.9 (6.0)  
Median change (Q1; Q3) -5.0 (-15.8; -1.5) -3.4 (-8.7; -0.3) -1.7 (-7.4; -0.2) -3.3 (-8.5; -0.3) 
Resolution of inflammation#  n=107 n=54 n=49 n= 10 
6 weeks: n (%) 11 (10.3) 8 (14.8) 6 (16.2)  0 (0.0)  
 n= 108 n=55 n=38 n=10 
Final visit: n (%) 20 (18.5) 12 (21.8) 10 (26.3) 1 (10.0)  
AUC for weekly pain in 1st six weeks (range 0 to 20); 
high score = worse 
n=77 n=37 n=24 n= 7 
Mean (SD) 7.6 (5.2) 5.4 (5.2) 5.6 (5.2) 7.3 (6.3) 
DLQI (range 0 to 30); high score = worse n = 111 n=66 n=49 n= 10 
Baseline: mean (SD) 11.7 (8.2) 8.4 (6.0)  8.5 (6.0) 8.8 (4.6) 
 n = 66 n=49 n=32 n= 10 
Final visit: mean (SD) 5.5 (7.2) 6.2 (6.8) 7.6 (7.5) 4.6 (5.4) 
EQ-5D* (range 0 to 1); high score = better n=108 n= 66 n= 49 n= 10 
Baseline: mean (SD) 0.48 (0.4) 0.59 (0.3) 0.60 (0.3) 0.51 (0.3) 
 n = 69 n= 51 n= 34 n= 10 
Final visit: mean (SD) 0.71 (0.4) 0.69 (0.3) 0.65 (0.3) 0.73 (0.3) 
EQ-5D VAS (range 0 to 100); high score = better n =110 n= 66 n= 49 n= 10 
Baseline: mean (SD) 62.0 (21.8) 67.0 (20.4) 65.6 (21.9) 64.4 (15.9) 
: n = 70 n= 50 n= 33 n= 10 
Final visit: mean (SD) 72.1 (21.2) 73.6 (20.5) 69.3 (22.2) 78.2 (13.1) 
Recurrence (in those who had healed by 6 months)$ n=52 n=27 n=19 n= 5 
n (%) 15 (28.8) 4 (14.8) 4 (21.1) 0 (0.0)  
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# Assessed by clinician, resolution of inflammation defined as erythema and border elevation reduced to 
“none” – as per Foss 7. $ Minimum follow-up after healing: RCT (0 to 40.3 months); cohort (5.5 months to 
37.2), depending on when recruited. * Captures health utility based on responses (0 to 2) for mobility, self-
care, usual activities, pain/discomfort, anxiety/depression. 
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